Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging

Eligibility Criteria

• 1. between ages of 56-85 years
• 2. all participants must score 18 or above on Montreal Cognitive Assessment (MoCA);
• 3. all participants must have a clinical dementia rating (CDR) Sum of boxes \<1;
• 4. need to be willing to undergo CSF LP on two occasions over the course of their participation,
• 5. need to be able and willing to stop using any prescription or non-prescription sleep aids (e.g.(e.g. Ambien, Sonata, Lunesta, Belsomra, Rozerem, Halcion, Intermezzo, Doxepin, Melatonin, etc.) for the duration of the study except for study-issued medications
• 6. BMI \< 35 at the time of enrollment
• 7. willing to bring a study partner (spouse, child or friend) who knows them well to each of the four visits
• 1. Individuals with any of the following conditions/ diseases will be excluded:
• 2. CDR\>=1, clinically significant depression/anxiety (GDS\>=9; GAI\>=9 ),
• 3. Participants who are on any of the following medications will be excluded: Fluvoxamine (Luvox)/ Fluoxetine (Prozac), Nifedipine (a blood pressure medication), all anti-coagulants (e.g. Warfarin, Coumadin, Heparin, , Lovenox, Xarelto, Pradaxa, etc.), anti-seizure drugs (e.g. Acetazolamide, Carbamazepine, Clobazam, Clonazepam, Gabapentin, etc.), muscle relaxants (e.g.Baclofen, Valium/ diazepam, Flexeril, etc.), or narcotic pain relievers (e.g.Codeine, Tramadol, Hydrocodone, Demerol, etc).